TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04360161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: swept-source optical coherence tomography
Description: Aswe pt-source OCT (CASIA SS-1000; Tomey Corporation, Nagoya, Japan), which is specifically designed for anterior segment imaging using a 1310 nm wavelength with a scan speed of 30,000 A-scans per second and an axial resolution of \<10 μm.
Study: NCT02120547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc in mild liver impaired
Description: Subjects with mild hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc in moderate liver impaired
Description: Subjects with moderate hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
Study: NCT00773253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.
Study: NCT04713085

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Sacral Neuromodulation
Description: Internal, implanted sacral nerve stimulation (electrodes in contact with neuronal fibers S3/4)
Study: NCT00773253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.
Study: NCT03134586

Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic imaging
Study: NCT02621996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hammock
Description: PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: containment nest
Description: In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation.
Study: NCT02413320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT01618097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD Decision Aid
Description: Patients will receive the DVD decision aid to view, and follow up 3 days and 30 days post visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Based Decision Aid
Description: Patients will receive the OA specific internet based decision aid to view, and follow up 3 days and 30 days post visit
Study: NCT01299363

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dilator use
Description: Women randomized to vaginal dilators will be given instructions to perform exercises with vaginal dilators from postoperative weeks 4 to 8
Study: NCT04713085

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive Sacral Neuromodulation
Description: External, non-invasive sacral nerve stimulation via two cutaneously adhesive electrodes (single current).
Study: NCT02212847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vestibular stimulation
Study: NCT00891735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Sterile solution for intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Sterile solution for intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Sterile solution for intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Sterile solution for intravitreal injection.
Study: NCT04345419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir as antiviral drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: Standard of care treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care treatment
Description: Standard of care treatment
Study: NCT02183714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Songha Night ®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01486862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
Study: NCT01995929

Intervention type: PROCEDURE
Intervention: transnasal functional endoscopy
Study: NCT02964156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supersole
Description: A 4-mm thin, individually customized insole of a malleable plastic material (CI-Core®) with synthetic textile material on the upper side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention
Study: NCT03807531

Intervention type: DEVICE
Group type: OTHER
Intervention: Temporary Spur Stent System
Description: Participating subjects that meet inclusion and exclusion criteria will undergo treatment of infrapopliteal occlusions and stenoses with the Temporary Spur Stent System according to protocol guidelines
Study: NCT01454804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Starting dose 500 mg by mouth every day for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin®)
Description: 4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.~Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.~Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting dose 200 mg by mouth every day for 28 days.
Study: NCT03156036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine plus temozolomide VS Capecitabine
Description: For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine plus temozolomide VS Capecitabine
Description: For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine plus temozolomide VS Capecitabine
Description: For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine plus temozolomide VS Capecitabine
Description: For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day
Study: NCT00954395

Intervention type: OTHER
Intervention: D-dimer
Description: D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.

Intervention type: OTHER
Intervention: D-dimer
Description: D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.
Study: NCT03585790

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with Multifocal Optics
Description: This contact lens has optics to aid the accommodative and convergence systems

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with Multifocal Optics
Description: This contact lens has optics to aid the accommodative and convergence systems
Study: NCT02506738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention using mHealth
Description: Patients in the intervention used at home a mobile system to monitor their clinical and health status.
Study: NCT03585790

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with Single Vision Optics
Description: This contact lens has standard single vision optics

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lens with Single Vision Optics
Description: This contact lens has standard single vision optics
Study: NCT03479749

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: RegenoGel-OSP, RegenoGel
Description: RegenoGel-OSP (A) and RegenoGel (B) are visco-supplements intended for the intra-articular treatment of OA.
Study: NCT00323882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX-010
Description: selected dose administered IV every 3 weeks
Study: NCT02682238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000, 15%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study: NCT03479749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RegenoGel-OSP, RegenoGel
Description: RegenoGel-OSP (A) and RegenoGel (B) are visco-supplements intended for the intra-articular treatment of OA.
Study: NCT03846765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period.
Study: NCT03212339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic intervention
Description: Therapeutic interventions will be delivered in ten 2-hour sessions over 12-15 weeks, which includes 2 research data collection sessions at the beginning of the study (pre-intervention) and at the end of the study (post-intervention). During the pre-intervention data collection session, participants will be asked to provide demographic information and complete interviews about their past experiences and current experiences as a parent, and their child's current functioning. Parents will also be video recorded interacting with their child for 10 minutes. During the post-intervention data collection session, participants will be asked to complete a similar set of interviews and will also be video recorded interacting with their child for 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic intervention
Description: Therapeutic interventions will be delivered in ten 2-hour sessions over 12-15 weeks, which includes 2 research data collection sessions at the beginning of the study (pre-intervention) and at the end of the study (post-intervention). During the pre-intervention data collection session, participants will be asked to provide demographic information and complete interviews about their past experiences and current experiences as a parent, and their child's current functioning. Parents will also be video recorded interacting with their child for 10 minutes. During the post-intervention data collection session, participants will be asked to complete a similar set of interviews and will also be video recorded interacting with their child for 10 minutes.
Study: NCT03128723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acne Mask
Description: The light therapy acne mask contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes.
Study: NCT03660384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPV/SO
Description: Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPV/C3F8
Description: Subjects receive 16% C3F8 gas tamponade during vitrectomy
Study: NCT03106662

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10\^8 cell/kg mesenchymal stem cells will be infused.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide administration
Description: After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day.
Study: NCT01975623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARMONIC ACE®+ Shears (HS)
Description: We plan to evaluate the efficacy of the HS for the sealing of PAs in an ex-vivo human model. Efficacy will be measured and compared using the bursting pressure point following vascular energy sealing. Energy sealing may be superior to stapling devices as it eliminates the need for excessive tissue dissection around the pulmonary vessels, which in turn decrease the incidence of vascular injuries during VATS anatomical lung resection. All vessels will be sealed ex-vivo using the HARMONIC ACE®+ Shears (Ethicon, Cincinnati, Ohio, USA).
Study: NCT04656223

Intervention type: COMBINATION_PRODUCT
Intervention: MF/IND/GLY plus sensor system
Description: There is no treatment allocation. Patients administered MF/IND/GLY plus sensor system by prescription that have started before inclusion of the patient into the study will be enrolled.~Subjects will receive MF/IND/GLY together with the Propeller add-on sensor for the Breezhaler® according to label.

Intervention type: DRUG
Intervention: FDC therapy
Description: There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT01331187

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pocket-size ultrasonography
Description: Routinely adding a ultrasound examination of the heart, pleura, great abdominal vessels, liver/gall bladder and kidneys at patients admittance to hospital
Study: NCT03926143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9343 (Anetumab ravtansine)
Description: BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies
Study: NCT01331187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: No intervention, except for usual care (goal-directed diagnostics)
Study: NCT01641068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention
Description: Participate in memory and thinking skills workshop

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Participate in workshops focusing on increasing knowledge and education on the brain and cognition

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging
Description: Undergo functional neuroimaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Magnetic Resonance Imaging
Description: Undergo functional neuroimaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memory Intervention
Description: Participate in memory and thinking skills workshop

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03374462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Intervention
Description: Home-based telemedicine visits
Study: NCT02527382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed stump
Description: Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a bowel clamp is placed on the rectal stump. A second bacterial sample is obtained at the completion of the anastomosis from the same place (pelvic pouch) as the first one.
Study: NCT02960594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-1401
Study: NCT02442934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Administration of the IPREA3 questionnaire
Description: On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administration of the IPREA3 questionnaire
Description: On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate feedback through electronic reminder messages
Description: After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted interventions in each ICU to reduce discomforts
Description: These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures.
Study: NCT02989233

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Scaling and oral hygiene instructions with brochure, model or video